OSUR vs RNA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
OSUR presents a stark contrast between a fortress-like balance sheet and a deteriorating business model. While the Piotroski F-Score of 6/9 indicates stable financial health and the company maintains exceptional liquidity (Current Ratio 6.58) with negligible debt, the operational metrics are alarming. Revenue has contracted by 28.5% YoY, and profit margins are deeply negative at -59.76%. Despite trading at a significant discount to book value (P/B 0.67), the lack of growth and consistent earnings misses suggest a value trap.
RNA exhibits critical financial distress, characterized by a Piotroski F-Score of 4/9 which barely maintains a 'stable' rating despite catastrophic liquidity metrics. The company is facing a severe solvency crisis with a Current Ratio of 0.07 and a negative Price/Book ratio of -3.57, indicating negative shareholders' equity. Revenue has collapsed by 71.10% YoY, and the company has missed earnings estimates in 100% of the last four quarters. Combined with aggressive insider selling by the CEO and CFO, the fundamental outlook is extremely poor.
Compare Another Pair
Related Comparisons
OSUR vs RNA: Head-to-Head Comparison
This page compares OraSure Technologies, Inc. (OSUR) and Atrium Therapeutics, Inc. (RNA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.